Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01190813 · ClinicalTrials.gov registry record · Phase 3

Levodopa for the Treatment of Residual Amblyopia

A Phase 3 study of Amblyopia, sponsored by Jaeb Center for Health Research.

Completed
Registry status
Phase 3
Development phase
139
Enrollment target
1
Study location

NCT01190813 is a Phase 3 study of Amblyopia that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 139 participants, below the 160-participant average among 24 other Amblyopia trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01190813, a Phase 3 study of Amblyopia, has completed, sponsored by Jaeb Center for Health Research.

COMPLETED
Registry status
Phase 3
Development phase
139 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the efficacy and safety of oral levodopa and patching versus oral placebo and patching as treatment for residual amblyopia in children 7 to \<13 years old with visual acuity of 20/50 to 20/400 in the amblyopic eye.

Conditions Studied

Amblyopia

Interventions

  • DRUG Placebo
  • OTHER Patching
  • DRUG Levodopa/Carbidopa

Study Locations (1)

Maryland

  • Wilmer Eye Institute - Baltimore

Trial Details

FieldValue
Enrollment Target 139 participants
Start Date 2010-09
Est. Completion 2014-04
Phase Phase 3

Sponsor

Jaeb Center for Health Research

119 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01190813

The ClinicalTrials.gov registry entry for NCT01190813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 24 other Amblyopia trials with a reported enrollment target (13% lower). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amblyopia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01190813 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01190813 about?

NCT01190813 is a clinical study titled "Levodopa for the Treatment of Residual Amblyopia". The purpose of this study is to evaluate the efficacy and safety of oral levodopa and patching versus oral placebo and patching as treatment for residual amblyopia in children 7 to \<13 years old with visual acuity of 20/50 to 20/400 in the amblyopic eye.

What is the current status of trial NCT01190813?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2010-09. Estimated completion is 2014-04.

What conditions does trial NCT01190813 study?

This clinical trial studies the following conditions: Amblyopia.

What interventions are being tested in trial NCT01190813?

The interventions under investigation include: Placebo (DRUG), Patching (OTHER), Levodopa/Carbidopa (DRUG).

Who is sponsoring clinical trial NCT01190813?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01190813 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amblyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Amblyopia

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.